BEXMAB study update
Faron Pharmaceuticals Oy ("Faron” or the “Company") Inside Information: Encouraging Additional Data for Bexmarilimab for the Treatment of Hematological Malignancies BEXMAB Study Update Two objective responses (ORR) and two stable disease (SD) patients, with one having > 50% reduction of blast cells, observed in the second doublet cohort Of the three patients with ORR in the first doublet cohort, two remain on the study after 10 and 9 months, respectively, and the third has undergone a potentially curative transplantation Second dose